Related Experiment Video
Updated: May 1, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer
Michael J McGuire1, Bethany Powell Gray1, Shunzi Li1
11] Departments of Internal Medicine, University of Texas Southwestern Medical Center 5323 Harry Hines Blvd. Dallas, TX 75390-8807, USA [2] The Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center 5323 Harry Hines Blvd. Dallas, TX 75390-8807, USA.
Abstract:
Tumor targeting ligands are emerging components in cancer therapies. Widespread use of targeted therapies and molecular imaging is dependent on increasing the number of high affinity, tumor-specific ligands. Towards this goal, we biopanned three phage-displayed peptide libraries on a series of well-defined human non-small cell lung cancer (NSCLC) cell lines, isolating 11 novel peptides. The peptides show distinct binding profiles across 40 NSCLC cell lines and do not bind normal bronchial epithelial cell lines. Binding of specific peptides correlates with onco-genotypes and activation of particular pathways, such as EGFR signaling, suggesting the peptides may serve as surrogate markers. Multimerization of the peptides results in cell binding affinities between 0.0071-40 nM. The peptides home to tumors in vivo and bind to patient tumor samples. This is the first comprehensive biopanning for isolation of high affinity peptidic ligands for a single cancer type and expands the diversity of NSCLC targeting ligands.
Insights
Researchers identified 11 novel peptides targeting non-small cell lung cancer (NSCLC) cells. These high-affinity ligands show potential for cancer therapies and molecular imaging, correlating with tumor genotypes.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Targeted cancer therapies and molecular imaging require high-affinity, tumor-specific ligands.
- Developing novel ligands is crucial for advancing personalized cancer medicine.
Purpose of the Study:
- To discover and characterize novel peptidic ligands for non-small cell lung cancer (NSCLC).
- To assess the potential of these ligands for targeted therapy and molecular imaging applications.
Main Methods:
- Biopanning of three phage-displayed peptide libraries against well-defined NSCLC cell lines.
- Characterization of peptide binding profiles across 40 NSCLC cell lines and normal bronchial epithelial cells.
- Assessment of multimerized peptide binding affinities and in vivo tumor homing capabilities.
Main Results:
- Isolation of 11 novel peptides with distinct binding profiles across NSCLC cell lines.
- Peptide binding correlated with specific onco-genotypes and EGFR signaling pathways.
- Multimerized peptides achieved high-affinity binding (0.0071–40 nM) and demonstrated in vivo tumor homing.
- Peptides successfully bound to patient tumor samples.
Conclusions:
- This study represents a comprehensive biopanning effort for NSCLC-specific ligands.
- The identified peptides expand the repertoire of NSCLC targeting ligands and show promise as surrogate markers for targeted therapies and imaging.
More Related Videos
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
